GRAL GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Sunnyvale, California.…
Industry Peers
Diagnostics & ResearchKey Statistics
About GRAIL (NASDAQ: GRAL)
›
GRAIL (NASDAQ: GRAL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 910 employees.
The shares were at 99.25 USD on 20 November 2026, up 24.0% over 52 weeks. Its 52-week range is 41.50 USD to 166.48 USD: the price is 40.4% below the high and 139.2% above the low.
Its market capitalisation is 4.46B USD.
GRAIL reports return on equity of -15.8%, an operating margin of -332.0% and revenue up 3.7% year over year.
It holds more cash than debt, a net cash position of 702.83M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 139.44 USD is 40.5% above the current price. The next earnings report is expected on 18 February 2027.